HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone.

Abstract
Recently, the Clinical Pharmacogenetics Implementation Consortium (CPIC) have revised recommendations for the translation of CYP2D6 genotype to phenotype. Changes affect phenotype grouping, as well as the value used to calculate activity score for the CYP2D6*10 allele to better reflect the substantially decreased activity of this allele which is the most frequent allele found in Asian populations. This study aimed to evaluate whether the lower value for CYP2D6*10 as recommended, and the revised phenotype groupings improve the relationship between CYP2D6 genotype and risperidone measures. One hundred and ninety-nine children and adolescents with autism treated with a risperidone-based regimen for at least four weeks were included. CYP2D6 genotype was determined using the Luminex xTAG CYP2D6 Kit assay and translated into phenotype using different translation methods. Plasma concentrations of risperidone and 9-hydroxyrisperidone were measured using LC/MS/MS. Plasma levels of risperidone, risperidone concentration/dose ratio, and risperidone/9-hydroxyrisperidone ratio in patients with an activity score < 1 were significantly higher than those ≥ 1 (P value < 0.001 for all three parameters). Plasma risperidone levels and risperidone concentration/dose ratios were significantly higher in intermediate metabolizers (defined as AS = 0.25-0.75) than normal metabolizer (defined as AS = 1-2) patients (1.44 vs. 0.23 ng/ml, P < 0.001 and 1.63 vs. 0.29 ng/ml/ng, P < 0.001, respectively) as well as risperidone/9-hydroxyrisperidone ratio (0.20 vs. 0.04, P < 0.001). This is the first study in an Asian population utilizing the revised CPIC-recommended method for translating the CYP2D6 genotype to phenotype. In addition to validating that CYP2D6 genetic variation significantly impacts risperidone metabolism, we demonstrated that revised value for the CYP2D6*10 was superior for genotype to phenotype translation. However, at least for risperidone, subjects with an activity score of 1 presented as phenotypic normal, and not intermediate metabolizers, suggesting that phenotype classification is substrate dependent.
AuthorsYaowaluck Hongkaew, Andrea Gaedigk, Bob Wilffert, Nattawat Ngamsamut, Wiranpat Kittitharaphan, Penkhae Limsila, Chonlaphat Sukasem
JournalScientific reports (Sci Rep) Vol. 11 Issue 1 Pg. 4158 (02 18 2021) ISSN: 2045-2322 [Electronic] England
PMID33603025 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antipsychotic Agents
  • Cytochrome P-450 CYP2D6
  • Risperidone
  • Paliperidone Palmitate
Topics
  • Alleles
  • Antipsychotic Agents (therapeutic use)
  • Child
  • Cytochrome P-450 CYP2D6 (genetics)
  • Female
  • Gene Frequency (genetics)
  • Genotype
  • Humans
  • Male
  • Paliperidone Palmitate (therapeutic use)
  • Pharmacogenetics (methods)
  • Phenotype
  • Polymorphism, Genetic (genetics)
  • Risperidone (therapeutic use)
  • Thailand

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: